Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT07001865

Metabolically Healthy Obesity Increases the Risks of MASLD and Hyperuricemia

Although metabolically healthy obesity (MHO) is often considered a relatively benign obesity, its association with the risk of metabolic dysfunction-associated steatotic liver disease (MASLD) and hyperuricemia remains unclear. This study examined the associations between MHO and other metabolic-obesity phenotypes with MASLD and hyperuricemia, and explored the mediating roles of metabolic indicators.This study included 11,712 and 13,846 participants from a health examination cohort at the First Affiliated Hospital of Ningbo University for MASLD and hyperuricemia analyses, respectively. Participants were classified into four metabolic-obesity phenotypes, with MHO defined as obesity without metabolic syndrome components. The outcomes were MASLD and hyperuricemia. Cox regression and mediation analyses were conducted to assess associations and mediating effects.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Metabolic Dysfunction-Associated Steatotic Liver Disease Body Weight Hyperuricemia Metabolically Healthy Obesity Nutrition Disorders Nutritional and Metabolic Diseases Obesity Obesity, Metabolically Benign Overnutrition Overweight Pathologic Processes Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year–100 year

Sex eligibility

All sexes

Study type

Observational

Primary location

the First Affiliated Hospital of Ningbo University Ningbo, Zhejiang, China, 315000, Ningbo, Zhejiang Province 315000 Recruiting

Ningbo, China

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Underwent comprehensive health examinations at the Physical Examination Center of the First Affiliated Hospital of Ningbo University between 2017 and 2024;
  • Aged 18 years or older at baseline;
  • Completed an abdominal ultrasound examination during the health check-up.

Exclusion criteria

  • Underweight status at baseline, defined as BMI < 18.5 kg/m² ；
  • Missing data on height, weight, or components of the metabolic syndrome ;
  • Baseline diagnosis of MASLD or any other liver diseases
  • Baseline diagnosis of hyperuricemia

Treatment and study plan

Primary outcomes

  1. Incidence of MASLD and Hyperuricemia

    Time frame: 7 years

    through study completion

Sponsors and collaborators

Lead sponsor

Ningbo No. 1 Hospital

Other

Registry information

Official study title

Metabolically Healthy Obesity Increases the Risks of MASLD and Hyperuricemia: A Cohort Study With Mediation Analysis

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Jun 3, 2025
Registry last updated
Jun 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.